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ABSTRACT 
Background. Several uncontrolled studies encouraged the use of rituximab in patients with myositis. 
Unfortunately, the first placebo-phase trial in refractory myositis to assess the efficacy of rituximab, the 
Rituximab in Myositis trial, did not show a significant difference in the two treatment groups, although doubts 
have been expressed about its study design. In this review we present an up-to-date overview of the experiences 
of rituximab therapy in myositis.  
Methods. A PubMed search was performed to find all the available cases of refractory myositis patients treated 
with rituximab up to July 2015. The following terms were assessed: "inflammatory myopathies OR 
antisynthetase syndrome OR polymyositis OR dermatomyositis AND rituximab".  
Results. 48 studies were included in this review. We identified 458 patients with myositis treated with 
rituximab. Dermatomyositis was the most frequent disease (32.9%). The most common index manifestation for 
rituximab therapy was muscle weakness (89.7%). We found a rate of response to rituximab of 78.3%.  
Conclusions. Rituximab can play a role in the management of patients with myositis, most likely in those 
patients with myositis-specific autoantibodies.  
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INTRODUCTION 
The idiopathic inflammatory myopathies (IIM) are a group of acquired, heterogeneous, systemic diseases of 
skeletal muscle, including adult polymyositis (PM), adult dermatomyositis (DM), juvenile DM (JDM), juvenile 
PM (JPM), antisynthetase syndrome (ASS) and inclusion body myositis (IBM). Features common to all of these 
subtypes include muscle weakness, elevated serum levels of muscle enzymes, myopathic abnormalities on 
electromyography and inflammatory cell infiltrates on muscle biopsy. However, each subset has distinct 
clinical, histological and immune-pathological characteristics. 
Both DM and PM usually present with symmetrical and proximal muscle involvement, but in DM typical skin 
lesions can also occur. IBM is predominantly characterized by weakness and atrophy of distal muscles, 
especially wrist and finger flexors. 
As these conditions are rare, current treatment of myositis is based mainly on case reports and a few randomized 
controlled trials with small numbers of patients enrolled. As a result, the choice of treatment is often empirical. 
The general clinical consensus among physicians is to use high-dose corticosteroid therapy as the first-line 
option in patients with myositis. In order to avoid side effects, the prednisolone dose should be reduced based on 
patient’s clinical response (1). However, several patients discontinue steroid treatment early because of a lack of 
improvement and/or adverse events (2). In clinical practice, an immunosuppressive drug is often added as 
'steroid-sparing' agent or in corticosteroid-resistant patients or when disease relapses. Nevertheless, a Cochrane 
review concluded that there was insufficient evidence from the available studies to confirm the value of 
immunosuppressive agents in myositis (3).  
For refractory DM, intravenous immunoglobulin (IVIG) had short-term clinical efficacy in a double-blind, 
placebo-controlled trial (4). However, long-term safety and efficacy need to be tested. IVIG can be also 
effective in some difficult-to-treat patients with PM (5), but offers only partial and short-lived benefit to a small 
number of cases with IBM, which is refractory to most therapies (6). Cyclophosphamide and tacrolimus might 
be useful especially in patients with interstitial lung disease (ILD) and severe myopathy (6,7).  
In patients with myositis resistant to conventional treatment, Rituximab (RTX) is a potential treatment option. 
RTX is a chimeric monoclonal antibody binding the CD20 antigen expressed on the surface of B lymphocytes at 
most stages of their development, but not on pro-B cells, early pre-B cells and plasma cells. It results in rapid 
depletion of CD20 positive B lymphocytes from the peripheral blood for up to 6-9 months (8). Although 
beneficial effects of RTX have been suggested by case reports and case series, the experience in adult and 
paediatric patients with refractory myositis is limited. The determination of which subset(s) of patients is/are 
 4 
 
more likely to be responsive, when RTX should be administered during the disease course, whether to use 
combination therapies and the optimal regimen and schedule for re-treatment, remain to be elucidated. 
In this study we review the most significant published data regarding the use of RTX for patients with PM and 
DM and try to identify which group of patients might be the most likely to benefit from this treatment. 
 
MATERIALS AND METHODS  
We analysed current evidence on the therapeutic use of RTX in refractory patients with IIM by a review of the 
literature including articles published up to July 2015.This review was based on a bibliographic search in the 
PubMed database, using the following keywords: inflammatory myopathies OR antisynthetase syndrome OR 
polymyositis OR dermatomyositis AND rituximab. Furthermore, we also included some relevant studies not 
present in our PubMed search, but referenced in other articles. 
We considered case reports and open label studies according to the authors’ definition. We also subdivided case 
series papers in “large” if they have 4 or more cases and “small” if they have less than 4 subjects. 
A total of 48 articles were identified (table 1). In particular, we found 19 case reports, 4 open label studies, 24 
case series (8 small, 16 large series) and the Rituximab In Myositis (RIM) trial (9). 
 
REVIEW OF PATIENTS TREATED WITH RITUXIMAB  
In total, we identified 458 patients with IIM treated with RTX. DM was the most frequent disease reported in 
151 cases (32.9%). The response to RTX in refractory PM has been analysed in 144 patients (31.4%), including 
19 subjects with anti-signal recognition particle (anti-SRP) antibody positivity. In addition, RTX was 
administered to 79 patients with ASS (17.2%) and to 72 patients with JDM (15.7%). Only two patients were 
affected by IBM and undifferentiated inflammatory myositis (UI), respectively. In 10 cases, the IIM subtype is 
not specified.  
The most frequent refractory symptom, for which the RTX was administered, was muscle weakness (411/458; 
89.7%). There was some heterogeneity in the RTX regimen used. The majority of the patients that we reviewed 
(193/458; 42.1%) received the protocol widely used for rheumatoid arthritis (two infusions at a dose of 1000 mg 
of RTX, giventwo weeks apart). The lymphoma schedule (RTX at a dose of 375 mg/m2 weekly for four 
consecutive weeks) was administered in 38 patients. Other schedules (500mg at days 0 and 14 or 100mg/m2 
weekly for six consecutive weeks) were rarely used. Concomitant therapies were corticosteroids, methotrexate, 
mycophenolate, azathioprine, cyclophosphamide, cyclosporine or IVIG. In the RIM trial (9), RTX dosing was 
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based on the patient’s body surface area (BSA); children with a BSA ≤1.5 m2 received 575 mg/m2 at each 
infusion, and adults and children with a BSA>1.5 m2 received 750 mg/m2 up to 1 g. Moreover, patients were 
subdivided in two groups: 96 subjects received two RTX infusions at weeks 0 and 1 (early RTX group), whereas 
104 received the drug 8 weeks later (late RTX group).   
Overall, 359 (78.3%) out of 458 patients, affected by myositis refractory to conventional therapy, showed an 
improvement in one or more of the IIM manifestations after RTX treatment (table 1).  
RTX was generally well tolerated. The most common side effects were infections (mainly respiratory tract 
infections), of which approximately 5% were severe, requiring hospitalization. Infusion reactions rarely 
occurred; they were often mild and easily controlled with steroids. 
 
CONSIDERATION OF RITUXIMAB’S CURRENT ROLE IN THE TREATMENT OF MYOSITIS 
Due to the rarity and heterogeneity of IIM, the main concern with their treatment is the lack of adequate 
controlled trials, with only partially validated outcome measures. 
RTX was empirically used off-label in patients who did not show a good response to the conventional therapy. 
The reasons to try this approach were based on the evidence of circulating auto-antibodies in up to 80% of 
patients with IIM (10) and on the presence of B cells in the perivascular region of muscles in patients with DM 
and in the inflammatory muscle fibres in both PM and DM patients (11). Given the likely pathogenetic role of B 
cells in myositis and favourable data from B-cell depleting therapy from several case series, the largest clinical 
trial of RTX in myositis (RIM trial) was undertaken (9). In this study, 200 patients with refractory myositis (76 
with PM, 76 with DM, and 48 with JDM) were randomized to receive different regimens of RTX (2 infusions at 
baseline or 8 weeks later). Refractory disease was defined as the failure of steroids and at least one 
immunosuppressive agent, for a duration of at least 3 months of the agent at a known effective dose. Although 
the group treated with RTX at onset did not improve significantly earlier than the group treated after a delay of 8 
weeks (primary endpoint), the majority of patients (83%) responded to RTX treatment and a significant steroid-
sparing effect was reported. Twenty-six serious adverse effects attributed to RTX therapy were observed, most 
of which were infections. In an accompanying editorial (12), De Visser described several limitations of the RIM 
study, mainly concerning the trial design. The power calculation was based on the postulated effect of RTX by 8 
weeks, but an improvement was observed only after 20 weeks. The selection of a 8-week placebo phase was 
based on ethical considerations, but it was felt to be too short to detect a significant difference. Moreover, the 
core set of measures used was only partially validated. The selection of patients was performed according to the 
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Bohan and Peter criteria (13) and not with the most recent classification criteria (14). For these reasons, the trial 
was probably not powered to detect an effect of the RTX treatment. Thus, while formally negative, the results of 
the RIM trial did give some support for the idea that RTX might be an effective treatment strategy in IIM. 
In this review, we have observed a rate of therapeutic response to RTX of 78.3% (359/458 patients). To avoid a 
publication bias of case reports and small series, we subsequently excluded the case series of three or less from 
the calculation for the response rate. We found that, excluding these studies, 323 out of 420 patients responded 
to RTX treatment (76.9%). Interestingly, the majority of patients with myositis-specific auto-antibodies (MSA) 
positivity achieved a good response, often with long term remission (≥12 months). MSA are disease markers 
closely associated with clinical subsets of IIM and they are found in approximately 30-50% of the patients with 
myositis (15). The presence of these antibodies seems to predict a better response to B cell depleting therapies. 
Nalotto et al (16) described a significant improvement in 5 out of 6 patients after RTX treatment. Antibody 
positivity was found in each responder, supporting the idea of a role for B cells in pathogenesis of myositis. In a 
post-hoc analysis of the subgroups in the RIM trial, Aggarwal et al investigated predictors of clinical 
improvement in PM/DM patients treated with RTX (17). The positivity of a myositis autoantibody was the 
major predictive factor of clinical improvement following B cell depletion therapy (2-3 fold higher chances of 
improvement as compared to the negative autoantibody group). Among the autoantibody positive subset, 
patients with anti–Mi-2 or anti-Jo1 demonstrated greater improvement than patients with other MSA (such as 
anti-SRP, anti–TIF-1γ and anti-MJ) who showed only a non significant trend to faster time to response than 
antibody negative patients (hazard ratio:1.4).  
Interestingly, in many reports, levels of Jo-1 antibodies did not correlate with the disease course or relapse, but 
seem to remain stable (18–22). The probable explanation is that long-lived plasma cells producing auto-
antibodies are CD20-negative and are not affected by RTX. Moreover, the effect of RTX may be only partially 
related to blockade of the antibody production. RTX treatment may have an influence on other cells of the 
immune system, may ‘normalize’ auto-reactive T cells and re-establish the immune homeostasis (23).  
 The measurement of autoantibodies is also useful for predicting clinical manifestations and prognosis in 
patients with myositis. Anti–melanoma differentiation-associated gene 5 (MDA5) and anti–aminoacyl-tRNA 
synthetase (ARS) antibodies are associated with a high risk of ILD, which is one of the most common causes of 
mortality in IIM patients (24). However, ILD associated with these two antibodies showed different clinical 
courses and therapeutic responsiveness. Anti-MDA5-positive patients mostly developed acute, progressive ILD 
with more severe course and more refractory to treatment (24).  
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Several reports supported the beneficial effects of CD20 depletion therapy in refractory ILD. In the pilot study 
of Levine (20), a clinical response was observed in two anti-Jo1 positive patients with pulmonary involvement 
after RTX therapy. In 2009, a retrospective case series (25) reported a significant improvement on high-
resolution CT (HRCT) imaging and/or pulmonary function tests (PFTs) in seven out of 11 ASS patients with 
ILD, following 6 months of RTX. However, the main concern with these studies is the use of several 
immunosuppressive agents both prior to and following treatment with RTX. Subsequently, Marie et al (26) 
published results of seven anti Jo-1 positive patients with refractory ILD treated with RTX in combination only 
with steroids. After a year, all seven patients had amelioration or resolution of their pulmonary symptoms and 
significant improvement in PFTs and HRCT findings.  
A retrospective study analyzed fifty patients with severe ILD, progressing despite conventional  
immunosuppression, treated with RTX (27). 33 of whom had ILD associated with connective tissue disease 
(CTD). B-cell depletion was effective as rescue therapy, stabilizing and/or improving the pulmonary function in 
36 of 50 patients (72%). Interestingly, within the CTD-ILD cohort, patients with myositis were most likely to 
improve in PFTs (FVC and DLCO) following RTX therapy. To avoid potential effects of thoracic muscle 
weakness on the PFTs, Unger et al (28) analysed the total lung capacity (TLC) improvement. Again, six of eight 
patients responded and TLC was stable in the other two patients. Interestingly, data from a 52 month follow-up 
study (29) showed that the most beneficial effects on lung function were observed in patients with disease 
duration <1 year and acute onset of ILD.   
These findings suggest that MSA, which are important prognostic markers, may also predict RTX response in 
IIM. 
Accordingly to aethio-pathological criteria, targeting B cells may also be potentially useful in DM, which is 
classically considered an humoral mediated disorder (30). Paradoxically, a better response to B cell depleting 
therapy has been observed in patient with predominant muscle involvement than in those with DM and skin 
disease. In our review, 52.1% of patients with skin lesions responded to RTX, but we noted a high frequency of 
relapse (48.6%; 18/37 patients). In a subgroup of subjects enrolled in the RIM trial (31), muscle assessment was 
more responsive than cutaneous measures to RTX treatment. Moreover, RTX was ineffective in treating skin 
manifestations in eight patients reported by Chung et al (32). Photosensitive heliotrope rash and violaceous 
poikiloderma seem to be the DM manifestations more sensitive to RTX (33). In contrast, paraneoplastic skin 
lesions and calcinosis were often refractory to B cell depleting therapy (34,35). 
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In addition, the JDM group showed a more rapid improvement in the trial compared to either adult DM or PM 
group (9). However, this difference was not statistically significant between the treatment arms, possibly related 
to the too small sample size (17). 
These findings confirm the complexity of the disease and suggest that the depletion of B lymphocytes may be an 
useful therapeutic advance, but is not going to be a cure for IIM.  
In conclusion, although it is not yet possible to make definite recommendations, the global analysis of all cases 
of the literature support the off-label use of RTX in some patients with refractory myositis. The lack of validated 
criteria to evaluate clinical response and the concomitant use of immunosuppressive drugs limit the ability to 
determine the specific role of B cell depletion therapy. Further studies of RTX in myositis are needed, 
particularly in treatment-naïve patients. 
 
 
 
Key Message:  
 RTX may be an effective strategy in the treatment of patients with refractory IIM. 
 Patients with autoantibodies, especially the anti-synthetases (mainly anti-Jo-1) and anti-Mi-2, were 
more likely to respond to RTX therapy. 
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Table 1. Summary of the general characteristics and response of patients with IIM to RTX therapy. 
References  
 
Type 
of 
study 
N. 
pts 
Disease Symptoms  RTX 
dosage 
Outcome  Response 
and comments 
Levine (20) Open 
Label 
6 
 
DM Skin lesions 
and myositis in 6 
pts; 
 ILD in 2pts 
375mg/m2 
weekly 
for 4 wks 
Improvement in 
muscle strength, CK 
levels, skin lesions. 
PFTs in 2 pts 
 
Response in all 
pts.4pts 
experienced a 
return of 
symptoms after 2-
9 months 
Lambotte 
(21) 
Case 
report  
1 ASS Myositis, ILD 375 mg/m2 
weekly 
for 4wks 
Improvement in 
MDS, CK and PFTs. 
Long-term 
Remission  
(12 months) 
Chiappetta 
(19) 
Case 
report 
 
1 DM Myositis, Skin 
lesions 
100 mg/m2 
weekly 
for 6wks 
Improvement in 
Muscle strength, CK 
levels, skin lesions. 
Long-term 
remission 
(20months). 
Retreatment with 
RTX every 
3months 
Gottenberg 
(36) 
Small 
series 
 
2 ASS Myositis 375 mg/m2 
weekly 
for 4 wks 
Improvement in 
Muscle strength, CK 
levels. 
Response 
Noss(37) Small 
series 
 
3  
 
2 PM 
1 DM 
 
Myositis in all pts. 
Arrhythmias 
in 2 pt. 
1 g I.V. at 
days 0 and 
14 
Improvement in 
Muscle strength, CK 
levels. 
 
Short term 
Response in 2pts 
(Relapse by 6–9 
months), Long 
term remission in 
1 pt with PM 
Brulhart (18) case 
report 
1 ASS Myositis, 
arthritis, alveolitis, 
rash 
1 g I.V. at 
days 0 and 
14 
Improvement in 
muscle strength, CK, 
CRP, and ESR levels, 
lung findings on CT 
scan. 
Short term 
Response. 
Relapse by8 
months. 
Urinary tract 
infection and 
acute sinusitis 
after RTX. 
Dinh(33) Small 
series 
 
3  
 
2JDM 
1DM 
Skin lesions 375 mg/m2 
weekly 
for 4wks 
Improvement in skin 
lesions. 
Response. 
Relapse by 9 
months in 1pt. 
Transient flu 
symptoms in 2 pts 
Chung (32) open-
label 
8 DM Skin lesions and 
Myositis 
1 g I.V. at 
days 0 and 
14 
At least 50% 
reduction in CK 
levels, muscle deficit 
(MMT) or skin 
disease (DM Skin 
Severity Index)at wk 
24. 
 
3 pts met criteria 
for improvement 
in muscle 
strength. No 
significant 
improvement in 
skin disease. CK 
levels not reflect 
muscle strength. 
Mok(38) Open 
Label 
4 PM  Myositis 375 mg/m2 
weekly 
for 4 wks 
 
Significant 
improvement in the 
mean proximal 
muscle power scores 
and reduction in CK 
levels. 
Response. There 
is also a trend of 
improvement in 
disability scores 
and in both the 
mental and 
physical 
components of 
SF-36 
Cooper(39) large 
series  
4  
 
JDM Myositis, skin 
Lesions 
375 mg/m2 
weekly 
for 4 wks 
improvement in skin 
lesions, CK, 
aldolase levels. 
Response in 3 pts. 
1 pt had a 
persistent disease. 
Touma(40) 
 
Case 
report 
 
1  
 
DM Myositis, 
skin lesions, cardiac 
involvement 
 
1 g I.V. at 
days 
0 and 14 
 
improvement in 
muscle strength, CK, 
ESR, CRP, 
CK-MB, TT, Holter 
ECG. 
Long-term 
remission 
Feist(41) Case 
report 
 
1  
 
DM Skin lesions, 
miositi 
1 g I.V. at 
days 
0 and 14 
 
Improvement in Skin 
lesions, muscle 
strength, 
CK. 
Long-term 
remission 
Lutt(42) Small 
series 
 
2 1DM 
1PM 
Skin lesions, 
miositi 
1 pt: 375 
mg/m2 
weekly 
For 2 
weeks; 1pt: 
1 g I.V. at 
days0 and 
14 
Improvement in Skin 
lesions, muscle 
strength, 
CK. 
 
Response but 
complications of 
mycobacterial 
infections 
Sultan (10) Open 
Label 
8 2 PM 
5DM 
1JDM 
Myositis in 8pts; 
ILD in 2pts; skin 
lesions in 1 pt; 
autoimmune 
thrombocytopenia 
in 1 pt 
1 g I.V. at 
days 
0 and 14 
 
Primary outcomes: 
≥15% improvement 
in muscle strength by 
myometry and 30% 
reduction in CPK at 
6months. 
 
2 pts with DM 
had a 
response.6pt were 
non-responder 
but:1pt 
subsequently 
diagnosed with 
IBMs. 1pt 
subsequently 
diagnosed with 
nodular 
sclerosing 
lymphoma;1pt 
subsequently 
diagnosed with 
sporadic 
dystrophy. 1pt 
died 1month after 
RTX. 
Vandenbrouc
ke(43) 
Case 
report 
1  ASS ILD 
 
1 g I.V. at 
days 0 and 
14 
Decrease of ground 
glass.  
Response 
Whelan(44) Small 
series 
2  
 
 
PM 
anti- 
SRP+ 
Myositis  1 g I.V. at 
days 0 and 
14 
Improvement in 
Muscle strength, CK 
levels. 
 
Poor clinical 
response. herpes 
zoster infection in 
1pt 
Sem(45) Large 
Series 
11 ASS ILD in 11 pts. 
Myositis in 5pts. 
1 g I.V. at 
days 0 and 
14 
Improvement in 
PFTs, HRCT, MMT, 
CK levels. 
 
Short-term 
beneficial 
effects.1 pt died of 
a Pneumocystis 
jirovecii infection 
Frikha(46) Small 
series 
2  
 
ASS Myositis in 2pts, 
ILD in 1pt 
 
1 g I.V. at 
days 0 and 
14 
Improvement in 
Muscle strength, CK, 
HRCT.  
Response 
Majmudar 
(47) 
Small 
series 
3 1DM 
1DM 
SRP+ 
1PM 
Myositis 1 g I.V. at 
days 0 and 
14 
Improvement in 
Muscle strength, CK 
levels. 
 
Response. 
Relapse by 12 
months in 2 pts 
(retreated) 
Rios 
Fernández 
(35) 
Large 
series 
4 3 DM 
1ADM 
Myositis, Skin 
lesions. 
ILD in 1pt 
375 mg/m2 
 weekly 
for 4 wks 
 
Improvement in 
Muscle strength, CK 
levels, skin lesions, 
and PFTs. 
 
Poor response in 
Paraneoplastic 
ADM. 
Valiyil(48) Large 
series 
 
8  
 
PM 
anti- 
SRP+ 
Myositis 1 g I.V. at 
days 0 and 
14 
Improvement in 
Muscle strength, 
CK levels 
 
Short-term 
beneficial 
effects in 6 pts.1pt 
died for 
pneumonia and a 
congestive heart 
failure 
exacerbation. 1pt 
lost to follow-up 
Zappa(22) Case 
report 
1 
 
ASS Myositis , ILD 
 
Not 
specified 
Improvement in 
Muscle strength, 
HRTC, PFTs and 
6-minute walking 
test.  
Response  
Jois(49) Case 
report 
 
1  
 
DM Myositis 1 g I.V. at 
days 
0 and 14 
 
Improvement in 
Muscle strength, CK.  
Long-term 
remission 
Mahler (15) Open 
label 
13  
 
5 DM 
8 PM 
Myositis  1 g I.V. at 
days 
0 and 14 
Primary outcome: 
Improvement in 
Muscle strength 
(hand-held 
dynamometry and 
MMT), in CK and 
LDH levels. 
Secondary outcomes: 
ESR and CRP level, 
VAS general 
Health, VAS disease 
activity and VAS 
pain, dosage of CS, 
functional ability, 
HAQ-DI,SF-36, 
plasma Ig 
concentrations and 
safety 
 
CPK and 
LDH normalized, 
and muscle 
strength measured 
by hand-held 
dynamometry 
increased by 
21.5%. MMT 
improvement did 
not reach 
statistical 
significance. 
Secondary 
outcome measures 
improved as well. 
3 pts remained in 
clinical remission, 
while 10 pts 
relapsed after a 
median of 7.4 
months. No 
differences 
between anti-Jo-
1- and anti-Jo-
1+pts 
Bader-
Meunier 
(34) 
Open 
label 
9 JDM Myositis in 7 pts, 
calcinosis in 1 pt, 
abdominal pain 
associated with 
abdominal 
lipomatosis in 1 pt 
375 mg/m2 
weekly 
for 4 wks 
in 7 pts; 
500 mg/m2 
at days 0 
and 14 
 in 3 pts 
Significant 
improvement in 
Muscle strength, CK, 
calcinosis. 
 
Response in 3pts 
treated for muscle 
involvement. 
Calcinosis and 
abdominal pain 
did not improve. 
Plasma exchange 
associated in 3 
pts. 5 pts received 
IGIV after RTX. 
Gheita(50) Case 
Report 
1  
 
PM Myositis 500 mg 
I.V. at 
days 0 and 
14 
Significant 
improvement in 
Muscle strength, CK.  
Response 
Couderc 
(51) 
 
Large  
series 
 
30 6 DM 
12PM 
12 
ASS 
Myositis in all pts 25pts: 1 g 
I.V. 
at days 0 
and14 
5pts: 375 
mg/m2 
weekly for 
4 wks 
Significant 
improvement in3 
criteria(>25%): 
CK, daily CS dose, 
physicians’opinion. 
Response in 16pts 
(duration 15.5 
months).5 pts had 
a history 
ofcancer.9pts had 
a systemic disease 
associated with 
the IIM. MMT 
done only in 5pts. 
Marie (26) Large 
series 
 
7 ASS ILD 1 g I.V. at 
days 0 and 
14 
Significant 
improvement of 
pulmonary 
symptoms, PFTs 
(FVC and DLCO) 
and HRCT findings. 
Clinical Response 
in all pts. 
Improvement in 
HRCT in 
5pts.(The 2 
remaining pts had 
no progression of 
ILD at 1-year 
follow-up) 
Parziale 
(52) 
Case 
report 
1 DM with 
AR 
Myositis 375 mg/ 
m2 weekly 
for 
4 wks 
Improvement in 
strength and CK. 
 
Long term 
remission 
Limaye(53) Case 
report 
1 ASS Myositis 500 mg/ 
m2 weekly 
for 
4 wks 
 
Improvement in 
muscle strength and 
CK. 
Response. 
2 relapse 
successfully 
retreated. 
Subsequent 
diagnosis of 
cervical intra-
epithelial 
neoplasia 
Luca (54) Case 
report 
1 JDM 
anti- 
SRP+ 
Myositis 500 mg 
I.V. at 
days 0 and 
14 
 
Significant 
improvement in 
Muscle strength, 
CMAS 
and in CK levels 
Response  
Sánchez-
Fernández 
(55) 
Small 
series 
2 1PM 
1DM 
Myositis 1 g I.V. at 
days 0 and 
14 
Improvement in 
muscle strength and 
CK levels. 
 
Long-term 
remission 
Oddis(9) Trial 195 ‘RTX 
early’  
37 PM 
36 DM 
23 JDM 
‘RTX 
late’ 
39 PM 
40 DM 
25 JDM 
 
Myositis 575mg 
 mg/m2 up 
to  
1g/infusion 
based on 
BSA. 
‘early’ 
arm: RTX 
atwks 0 
and 1. 
‘late’ arm: 
RTX at 
wks8 and 
9. 
Primary endpoint: 
time to achieve the 
IMACS DOI. 
Secondary endpoints: 
time to achieve ≥20% 
improvement in 
muscle strength, and 
the proportion of pts 
achieving DOI at wk 
8. 
It failed to 
achieve its 
primary and 
secondary 
endpoints 
Clottu(56) Case 
report 
1 DM 
anti-
MDA5+ 
Skin lesions 1 g I.V. at 
days 0 and 
14 
Improvement in skin 
lesions.  
Response 
Salimbene 
(57) 
Case 
report 
1 DM 
 
Myositis Not 
specified 
Improvement in 
muscle strength and 
CK levels. 
 
Response. 2 yrs 
after RTX, the pt 
developed a 
pulmonary 
infection 
Nalotto(16) Large 
series 
6 3PM 
3 ASS 
Myositis in 6pts. 
Arthritis in 2 pt. 
ILD in 1 pt. 
1 g I.V. at 
days 0 and 
14 
Improvement in 
muscle strength 
(MMT8) and CK 
levels. Disease 
activity score (in 2 
pts).  
Improvement in PFTs 
(in 1 pt). 
Long term 
remission in 5 
pts.1 pt no 
responder. 
 
Cuttner (58) Large  
series 
10 6DM 
1 
ADM 
3PM 
Myositis in 9pts. 
Skin lesions in 7 
pts. 
375 mg/ 
m2 
weekly for 
4 wks 
 
Improvement in skin 
lesions, muscle 
strength and CK 
levels. 
 
Partial response 
was achieved in 
all 10 pts, with a 
complete response 
reached in8pts. 
Muñoz-
Beamud 
(59) 
Large  
series 
 
16 2 PM 
2PM/RA 
1 ADM 
1JDM 
1DM/SC
L 
2DM/SL
E 
4ASS 
3DM 
Myositis 1 g I.V. at 
days 0 and 
14 
Improvement of at 
least 20% on 
theMITAX baseline 
score and a 
decreaseof at least 
30% of CK levels. 
 
MITAX Response 
in 8pts: 4ASS, 
2DM/ SLE and 
1PM/RA andthe 
ADM. Long term 
remission in 5/8 
pts. 10 pts showed 
at least 30% 
reduction in 
serum CK.No 
clinical response 
was correlated to 
the MITAX score 
in 2 out of these 
10 
Néel(60) Case 
report 
1 DM ILD 1 g I.V. at 
days 0 and 
14 
Improvement in 
dyspnea, PFTs and 
HRTC lesions. 
Response  
Basnayake 
(61) 
Large  
series 
 
7 1UI 
2DM 
4PM 
Myositis in 6pts. 
ILD in 5 pts 
1g at 
days0and 
14 in1 pt. 
500m/m2 
weekly 
for4 wks 
in4pts. 
750mg/m2
weekly for 
4wks in 2 
pts. 
Significant 
improvement in 
Muscle strength and 
CK levels. 
Improvement in 
PFTs.  
Response 
continued for at 
least5 months. 
Unger (28) Large  
series 
 
18 13 PM,  
5 DM 
myositis  
(in 12 pts),  
 ILD  
(in 11 pts), 
Arthritis 
(in 7 pts). 
12pts:  
1 g I.V. 
at days 0 
and 14. 
6pts: 375 
mg/m2 
weekly for 
4 wks 
 
reduction of >50% of 
both the baseline CK 
level and the daily CS 
dose or an increase of 
>10% of FVC and 
TLC baseline value.  
9 of 13 PM pts 
responded. all 5 
DM pts 
responded. 
Mecchella(62) Case 
report 
1 ADM ILD 1 g I.V. at 
days 0 and 
14  
Improvement in 
dyspnea and 
stabilized lung 
function 
Response but the 
pt developed 
Babesia microti 
infection 
Andersson 
(29) 
Large  
series 
 
24 ASS ILD 1 g I.V. at 
days 0 and 
14  
 
 
Improvement in PFTs 
and in HRCT images. 
Long term 
remission. 21% of 
the patients died. 
Most of the deaths 
being related to 
infections. 
Rider (31) Trial 18 8 PM,  
5 DM,  
5 JDM 
Myositis in all pts, 
skin lesions in 10 
pts. 
6Pts 
(early 
group): 
RTX at 
wks 0 and 
1; 
12 pts(late 
group) : 
RTX at 
wks 8 and 
9  
The primary DOI was 
met if, at 2 
consecutive visits, 
there was ≥20% 
improvement in 3 of 
6 core set activity 
measures. 
8 (44%) pts met 
the DOI by wk 16, 
and 15 met the 
DOI by week 44. 
50% of pts met a 
DOI 50% 
response and 22% 
met a DOI 70% 
response. The 
muscle 
assessments were 
more sensitive to 
change than skin 
assessments. 
Belhassen-
Garcia (63) 
Case 
report 
1 PM Myositis 375 mg/ 
m2 
weekly for 
4 wks 
 
Improvement in 
Muscle strength, CK 
levels. 
Response but 10 
months later, the 
pt showed 
progressive 
multifocal 
leukoencephalopa
thy 
Carolina 
Muñoz 
Grajales 
(64) 
Case 
report 
1 JDM Myositis Not 
specified 
Improvement in 
Muscle strength, CK 
levels. 
No responder 
Keir (27) Large 
case 
series 
10 IIM ILD 1 g I.V. at 
days 0 and 
14  
 
Improvement in PFTs  5 responders. 
Within the CTD-
ILD group, 
patients with IIM 
were most likely 
to show an 
improvement in 
PFTs following 
RTX 
 
 
Abbreviations: IIM: idiopathic inflammatory myopathies; PM: polymyositis; DM: dermatomyositis; JDM: juvenile 
DM; ADM: amyopathic DM; ASS: antisynthetase syndrome; IBM: inclusion body myositis; ILD: interstitial lung 
disease; CTD: connective tissue disease; SLE: systemic lupus erythematosus; SCL: systemic sclerosis; RA: rheumatoid 
arthritis; RTX: rituximab; pt: patient; wk: week; PFTs: pulmonary function tests; CS: corticosteroids; DOI: definition of 
improvement; MMT: Manual Muscle Testing; VAS: visual analogue scale; MDS: Muscle disability scale; CMAS: 
Childhood Myositis Assessment Scale; MITAX: myositis intention to treat activity index; SRP: signal recognition 
particle; MDA5: Anti–melanoma differentiation-associated gene 5. 
 
 
